Completed PHASE2 INTERVENTIONAL 2-arm NCT04854811

Roflumilast to Treat Cognitive Sequela After Stroke (ROSTMEMA)

A Proof of Concept Phase II Study With the PDE4 Inhibitor Roflumilast in People Suffering From Long-term Cognitive Sequela After Stroke

Sponsor: Maastricht University

Conditions Cerebrovascular Disorders Drug Intervention Functional Recovery Memory

Interventions Roflumilast Oral Tablet

Updated 8 times since 2021 Last updated: Jan 15, 2024 Started: Jul 7, 2021 Primary completion: Dec 1, 2023 Completion: Dec 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Cerebrovascular Disorders and Drug Intervention, this trial is completed. The trial is conducted by Maastricht University and has accumulated 8 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Feb 2024 — Jul 2024 [monthly]

Completed PHASE2

Status: Active Not Recruiting → Completed
Apr 2023 — Feb 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Nov 2021 — Apr 2023 [monthly]

Recruiting PHASE2

▶ Show 3 earlier versions

Oct 2021 — Nov 2021 [monthly]

Recruiting PHASE2
Jun 2021 — Oct 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
May 2021 — Jun 2021 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Maastricht University
Netherlands Brain Foundation

Data source: Maastricht University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Maastricht, Netherlands